Updated
Updated · Bloomberg · Jun 18Kardigan Raises $400 Million in Upsized US IPO at $16 a Share
3 articles · Updated · Bloomberg · Jun 18Summary
- $400 million was raised by Kardigan after the heart-health biotech priced 25 million shares at $16 each in its US IPO.
- The deal was upsized from a plan to sell 23.3 million shares and priced at the top of the marketed $14-to-$16 range, signaling strong demand.
- The offering gives public-market backing to a biotech focused on heart health as new US listings continue to test investor appetite.
Insights
After its $400M IPO, will Kardigan become the next Gilead or a quick acquisition for big pharma? Will Kardigan’s AI platform deliver functional cures or just fuel another biotech market bubble? Does this IPO signal a true biotech resurgence, or are investors just chasing de-risked assets?